LOXL3 and metastatic colorectal cancer: Barbazan et al. (2014) assessed the prognosis of patients with metastatic colorectal cancer (mCRC) using six prognostic markers, including LOXL3, and the clinical utility of prognostic tools, the results showed that the survival time of patients with high CTC markers was significantly shortened.